Karthik Ramasamy
Clinical Lead/ Director of Oxford Translational Myeloma Centre
IMPROVING OUTCOMES FOR PATIENTS WITH PLASMA CELL DYSCRASIAS
Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Translational Myeloma Centre, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group.
He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK and leads the National Haemonc Oversight Specialty group. He is an Executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance.
Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy with collaborators is developing a national advisory service for Castleman disease. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his academic research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 100 papers and authored textbooks/ chapters on myeloma.
Recent publications
-
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach.
Kannan A. et al, (2025), Blood rev
-
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.
Perrot A. et al, (2025), Eur j haematol
-
Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper.
Pinney J. et al, (2025), Br j haematol
-
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar R. et al, (2025), Indian journal of hematology and blood transfusion
-
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Ramasamy K. et al, (2024), Clin lymphoma myeloma leuk